Cellmid Limited operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Cellmid Limited with three other
companies in this sector in Australia:
Imugene Limited
(2019
sales of 4.54 million Australian Dollars [US$3.12 million]
of which 100%
was Health technologies),
Bionomics Limited
(4.03 million Australian Dollars [US$2.77 million]
of which 176%
was Contract Services), and
Immutep Ltd
(6.03 million Australian Dollars [US$4.14 million]
of which 93%
was Cancer Immunotherapy).
Sales Analysis.
Cellmid Limited reported sales of A$7.47 million (US$5.12 million)
for the
fiscal
year ending
June of 2019.
This
represents
an
increase of 29.6%
versus 2018, when the company's sales were A$5.76 million.
This was the fourth straight year of sales growth at Cellmid Limited.